Key facts
- Nuclivision’s last known valuation is $2.4M (Feb 2023).
- It has raised $6.0M; the latest was Early Stage VC ($5.5M) in Apr 2025.
- Notable investors include Imec.istart, Lumo Labs, HERAN Partners, Lumiares, Start It X — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Nuclivision
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuclivision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuclivision
Developer of a nuclear medicine software designed to assist in image acquisition, diagnosis, and follow-up. The company's platform improves efficiency and ease of integration by assessing metabolism at the cellular level, enabling doctors to scan more patients per day at a lower cost and helping patients by improving the accessibility of nuclear imaging.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2022
- Employees
- 10
- Website
- nuclivision.com/
- Ownership
- Privately Held (backing)
Nuclivision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuclivision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuclivision in its N-PORT filings yet. We sweep new filings monthly.